Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BioPharma APAC
biopharmaapac.com > news > 43 > 8380 > convergen-raises-15m-seed-to-accelerate-targeted-protein-degradation-therapies.html

Convergen Raises $15M Seed+ to Accelerate Targeted Protein Degradation Therapies

3+ hour, 2+ min ago   (60+ words) 02 September 2026 | Wednesday | News The proceeds will be used to further advance Convergen's proprietary degrader platform and accelerate its pipeline for neurodegenerative disorders and other protein aggregation diseases. Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence China Plus…...

biopharmaapac.com
biopharmaapac.com > news > 39 > 8255 > abbvie-launches-elahere-in-singapore-for-fr-positive-platinum-resistant-ovarian-cancer.html

AbbVie Launches ELAHERE in Singapore for FRα-Positive Platinum-Resistant Ovarian Cancer

1+ mon, 3+ day ago   (148+ words) 29 July 2026 | Wednesday | News ELAHERE is indicated as a monotherapy for the treatment of adult patients with folate receptor alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior…...

BioPharma APAC
biopharmaapac.com > news > 98 > 7849 > leinco-technologies-and-cellcarta-partner-to-advance-proteomics-in-immuno-oncology.html

Leinco Technologies And CellCarta Partner To Advance Proteomics In Immuno Oncology

4+ mon, 1+ week ago   (194+ words) BioPharma APAC - Leinco Technologies And CellCarta Partner To Advance Proteomics In Immuno Oncology 21 April 2026 | Tuesday | News Leinco Technologies, a leader in antibody and protein development, and CellCarta, a global provider of precision medicine laboratory services, are pleased to announce a…...

BioPharma APAC
biopharmaapac.com > news > 32 > 7841 > synthetic-design-lab-introduces-logic-gated-synthbody-platform-redefining-precision-protein-therapeutics.html

Synthetic Design Lab Introduces Logic Gated SYNTHBODY Platform Redefining Precision Protein Therapeutics

4+ mon, 1+ week ago   (134+ words) 20 April 2026 | Monday | News Similar early results were observed in a Non-Hodgkin's Lymphoma (NHL)-targeting SYNTHBODY™ construct, and a high-throughput SYNTHBODY ENGINE™ approach is being used to rapidly generate and optimize multiple solid tumor SYNTHBODY™ ADCs, supporting the platform's broad applicability…...

BioPharma APAC
biopharmaapac.com > news > 120 > 7789 > perceptive-discovery-expands-in-vitro-capabilities-to-accelerate-oncology-drug-development.html

Perceptive Discovery Expands In Vitro Capabilities To Accelerate Oncology Drug Development

4+ mon, 3+ week ago   (382+ words) BioPharma APAC - Perceptive Discovery Expands In Vitro Capabilities To Accelerate Oncology Drug Development 07 April 2026 | Tuesday | News Perceptive Discovery, a leading scientific partner to the global biopharmaceutical industry, announced a major expansion of its in vitro laboratory capabilities at its Needham,…...